AMI-193

AMI-193 is a serotonin antagonist and dopamine reuptake inhibitor that was under development by Amgen but was discontinued. It was being investigated for potential use in the treatment of schizophrenia and Parkinson's disease.

History

AMI-193 was developed by the biopharmaceutical company Amgen. The drug was in the early stages of development and was being tested for its potential use in the treatment of schizophrenia and Parkinson's disease. However, the development of AMI-193 was discontinued for undisclosed reasons.

Pharmacology

AMI-193 is a serotonin antagonist and dopamine reuptake inhibitor. This means it works by blocking the action of serotonin, a neurotransmitter that affects mood, and by preventing the reuptake of dopamine, another neurotransmitter that plays a role in reward and pleasure.

Potential Uses

Schizophrenia

AMI-193 was being investigated for its potential use in the treatment of schizophrenia. Schizophrenia is a mental disorder characterized by abnormal behavior, strange speech, and a decreased ability to understand reality. Current treatments for schizophrenia often have severe side effects, and there is a need for new treatments with fewer side effects.

Parkinson's Disease

AMI-193 was also being investigated for its potential use in the treatment of Parkinson's disease. Parkinson's disease is a long-term degenerative disorder of the nervous system that mainly affects the motor system. The symptoms generally come on slowly over time, and early in the disease, the most obvious symptoms are shaking, rigidity, slowness of movement, and difficulty with walking.

See Also

• Amgen
• Schizophrenia
• Parkinson's disease
• Serotonin antagonist
• Dopamine reuptake inhibitor

AMI-193 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia